Raynovent Announces Ethical Approval for Phase 2 Clinical Trial of Category 1 Drug ZSP1273.

Previous:Raynovent Announces Ethical Approval for Phase 1b /2a Clinical Trial of ZSP1601, a Category 1 Drug in Development for The Treatment of NASH.

Next:Raynovent Announces Receiving of Certificate of Invention Patent in Australia.